-
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study
•
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase III TORCHLIGHT study for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab). The study, which combines Tuoyi with paclitaxel and albumin, has completed its pre-set interim analysis for initially-diagnosed stage IV or recurrent metastatic triple-negative breast…
-
Abbott Partners with Sinopharm for Expanded Medical Solutions in China
•
US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical Device Co., Ltd. The collaboration aims to leverage the respective strengths of both companies in technology, service network, and other areas to enhance the distribution of advanced medical technologies and solutions in China. Partnership Scope…
-
Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a filing for another indication approval for its potassium-competitive acid blocker (P-CAB), tegoprazan. The drug is being reviewed for the treatment of duodenal ulcers, expanding…
-
Shanghai Pharmaceuticals’ X842 Accepted for NMPA Review for Reflux Esophagitis
•
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products Administration (NMPA) has accepted a market approval filing for its Category 1 gastric acid blocker, X842. The targeted indication for this innovative drug is reflux esophagitis (RE), a condition affecting a significant number of patients…
-
We-Linking Raises Tens of Millions in Angel Round for Brain-Computer Interface
•
We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly secured “tens of millions” of renminbi in an angel financing round. The funding round was led by Bluerun Ventures and CDH Investments, with participation from Naton Technology and Guokr.com. Company Background and AchievementsFounded in 2019,…
-
Hybio Pharma and CR Medicine Collaborate on Market Expansion
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot firm China Resource Medicine Commercial Holdings Ltd. The partnership aims to expand market reach, enhance promotion efforts, and boost sales. Financial details of the agreement were not disclosed. Hybio Pharma’s Strategic LeverageHybio Pharma, a key…
-
Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission of a market approval filing for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), to the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK. The company is seeking approval for the checkpoint inhibitor in…
-
Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy
•
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the enrollment and dosing of the first subject in a Phase I/II clinical study for its ophthalmology gene therapy ZVS101e in Tianjin. This study marks the first potentially regulatory clinical trial for a gene therapy targeting…
-
Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical study for its oral double prodrug ASC10. The findings were presented at the CROI 2023 annual meeting, marking a significant step forward in the development of this promising therapeutic candidate. Phase I Clinical Data HighlightsThe…
-
Beijing Huashen Shengdian Secures Angel Funding for Pelvic Surgery Monitor R&D
•
China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly secured an undisclosed amount of angel funding. The round was led by Tus Star, with participation from Wuxi Kelin Venture Capital Partnership. The proceeds will be directed towards accelerating the research and development of pelvic…
-
Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a significant milestone. The company’s generic version of AbbVie’s (NYSE: ABBV) bimatoprost and timolol maleate eye drops has been granted approval in China. This approval is for use in lowering the intraocular pressure of patients…
-
Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug limaprost. This therapeutic drug targets analgesia and microcirculation, addressing a significant health issue among the country’s population. Lumbar Spinal Stenosis: A Prevalent ConditionTubular stenosis, particularly lumbar spinal…
-
Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,” an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen’s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody…
-
Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study
•
Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the US FDA to initiate a Phase I/II clinical study for its BRG01, an autologous T cell therapy for the treatment of relapsed/metastatic nasopharyngeal cancer (NPC). This marks a significant milestone in the development of innovative…
-
China’s 8th Volume-Based Procurement Round Begins Drug Info Filing
•
The national drug alliance procurement office has released a notification initiating the drug information filing process for the 8th volume-based procurement (VBP) round. This round is a significant step in the ongoing efforts to streamline and optimize the procurement of pharmaceuticals in China. Registration and Information SubmissionAs of February 20,…
-
BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101
•
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major. The company reported the first cure in a multi-center Phase clinical study assessing the safety and efficacy of its BRL-101, an autologous hematopoietic stem progenitor cell therapy. This marks a major milestone in the development…
-
Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study
•
China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for its ICVAX, a therapeutic vaccine against HIV/AIDS, in Shenzhen. This marks a significant step forward in the development of innovative treatments for HIV/AIDS, a condition that affects millions of people globally. Study Design and ObjectivesThe…
-
Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover…
-
Hainan Honz Partners with GPI for Pediatric and Maternity Medicine Expansion
•
China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with Indonesia’s Global Putra International (GPI). The strategic collaboration is focused on multiple fronts, aiming to expand Hainan Honz’s pediatric and maternity medicines into overseas markets through the Regional Comprehensive Economic Partnership (RCEP) and Hainan free…
